Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001829126-25-006736 0001932843 XXXXXXXX LIVE 2 Common Stock, $0.01 par value 10/21/2025 false 0001389545 66987P409 NovaBay Pharmaceuticals, Inc. 2000 POWELL STREET, SUITE 1150 Emeryville CA 94608 DAVID E. LAZAR 646-768-8417 44, Tower 100, The Towers Winston Churchill San Francisco Paitilla Panama City R1 07196 0001932843 N David E. Lazar PF N S1 6388000.00 0.00 6388000.00 0.00 6388000.00 N 4.99 IN The amount reflected under "Sole Dispositive Power" consists of 6,388,000 shares of the Issuer's Common Stock, $0.01 par value per share (the "Common Stock") that were issued following the automatic conversion of the Issuer's Series D Convertible Preferred Stock, $0.01 par value per share (the "Series D Preferred Stock") as described in Item 6 below. Common Stock, $0.01 par value NovaBay Pharmaceuticals, Inc. 2000 POWELL STREET, SUITE 1150 Emeryville CA 94608 The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned ("Amendment No. 2"). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein. As a result of recent increases in the outstanding shares of Common Stock of the Issuer, the filing of this Amendment No. 2 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Person. The aggregate percentage of Shares owned by the Reporting Person is based upon 127,894,134 shares of Common Stock outstanding as of January 29, 2026 based upon information provided by the Issuer. As of the close of business on January 29, 2026, the Reporting Person beneficially owned 6,388,000 Shares. Percentage: Approximately 4.99% 1. Sole power to vote or direct vote: 6,388,000 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 6,388,000 4. Shared power to dispose or direct the disposition: 0 The transactions in the Shares by the Reporting Person during the past sixty days are set forth in more detail in Item 6. No person other than the Reporting Person is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares. Not applicable. Item 6 is hereby amended to add the following: At the Annual Meeting, the Issuer's stockholders approved, among other things, the conversion of Series D Preferred Stock into shares of common stock ("Stockholder Approval"). Three business days following such Stockholder Approval, all of the Reporting Person's Series D Preferred Stock was automatically converted into shares of the Issuer's Common Stock. David E. Lazar /s/ David E. Lazar David E. Lazar 01/29/2026